Introduction
Auraptene (7-Geranyloxycoumarin) is the most abundant prenyloxycoumarin found in (Curini et al., 2006) plants of the genus Citrus (Epifano et al., 2008) . Various dietary components like marmalades and grapefruit-derived products, such as juices, can contain significant amounts of auraptene, ranging from 0.11 to 0.38 mg/100 g in fresh products (Ogawa et al., 2000) .
Dietary administration of auraptene to animals has revealed numerous pharmacological activities. Auraptene induces anti-inflammatory, antioxidant antibacterial and immunomodulatory effects (Epifano et al., 2008) . Importantly, auraptene has been shown to protect rodents against chemically induced carcinogenesis ( Kohno et al., 2006; Krishnan et al., 2009; Tanaka et al., 2000; Tanaka et al., 1998) . It has also been reported to exert antiproliferative and pro-apoptotic activities on cancer cell lines such as human hepatocellular carcinoma, colorectal adenocarcinoma and breast adenocarcinoma cells in vitro (Krishnan et al., 2009; Ohnishi et al., 2004; Zheng et al., 2002) . Consequently, auraptene is potentially very interesting as a dietary chemopreventive agent for cancers. To date, little is known about the molecular mechanisms involved in the chemopreventive activity of auraptene against cancer or about its cellular effects.
The chemopreventive and the anticancer actions of auraptene suggest that it modulates one (or more) targets involved in the control of oncogenic processes. Our attention has been drawn to the targets of Tamoxifen (Tam), a drug that has been in use for more than 30 years for the treatment and the prevention of estrogen-receptor (ER) positive breast cancers (Jordan, 2007) and that has a complex pharmacology for which several targets have been identified. In addition to binding to ERs (Jensen and Jordan, 2003) , Tam has been shown to inhibit cholesterol esterification (de Medina et al., 2006; de Medina et al., 2004b; Payre et al., 2008) and to bind to the antiestrogen binding site (AEBS) with high affinity (Kedjouar et al., 2004) .
These additional targets account for the pharmacology of Tam (de Medina et al., 2004a) and are involved in its anticancer and chemopreventive activities (de Medina et al., 2009a; de Medina et al., 2009b; Payre et al., 2008) . Through a direct genomic mechanism, Tam modulates the transcription of genes under the control of ERs. ER modulators can produce a transcriptional signature that will differ according their chemical structure (McDonnell et al., 1995) and will affect the functionality of ERs by controlling their subcellular localization and stabilization (Wittmann et al., 2007) . SERM have been shown to block the mitogenic action of low doses of 17β-estradiol (E2) and to prevent against the occurrence of ER(+) breast cancers (Jordan, 2004) . More recently the importance of ERs in the etiology of colonic cancers was proposed and it was shown that ER modulation could reduce the formation of preneoplastic lesions in the colon (Weige et al., 2009 ) and control colon cancer cell proliferation and death (Booth et al., 1999; Janakiram et al., 2009; Xu and Thomas, 1994) showing that ER modulation could prevent the occurrence of colonic cancer.
We have reported that Tam inhibited the Acyl-CoA:Cholesterol Acyl Transferase (ACAT) activity in macrophages and tumor cell lines (de Medina et al., 2006; de Medina et al., 2004a; de Medina et al., 2004b; Payre et al., 2008) . Interestingly, cholesteryl esters have been reported to accumulate in tumors and to be involved in cell proliferation and invasiveness that are blocked by the inhibition of ACAT (Paillasse et al., 2009; Tosi and Tugnoli, 2005) . The AEBS is a hetero-oligomeric proteinaceous binding site made up of multifunctional enzymes involved in cholesterol metabolism (Kedjouar et al., 2004 ) that include cholesterol-5,6-epoxide hydrolase activity (ChEH) (de Medina et al., 2010) . We recently showed that Tam induced the differentiation and death of breast cancer cells through the accumulation of cholesterol precursors, and cholesterol oxidation products (de Medina et al., 2009a; de Medina et al., 2009b; Payre et al., 2008) . We have also done structure-function studies which allowed us to identify pharmacophores involved in the inhibition of ACAT (de Medina et al., Medina et al., 2006) and AEBS binding (Poirot et al., 2000) . The structure of auraptene led us hypothesize that it might modulate some of these targets of Tam which may explain its action in chemoprevention and cell growth control.
In the present paper we have compared auraptene to pharmacophores that target ERs, ACAT, and the AEBS, and characterized its effect on different tumor cell lines. We show that auraptene is a modulator of ERs and an inhibitor of cholesterol esterification. ICI 164, 3, 5(10 Basel, Switzerland) . Auraptene (7-Geranyloxycoumarin) and umbelliferone (7-hydroxycoumarine) were synthesized as previously described (Curini et al., 2004) . Other compounds and chemicals were from Sigma-Aldrich (St. Louis, MO), solvents from VWR (Fontenay sous Bois, France) and thin-layer chromatography (TLC) plates (LK-6-DF) were obtained from Whatman (Clifton, NJ).
Molecular Structure Analysis.
The structure analysis and the comparisons between the structure of compounds was done exactly as previously described (de Medina et al., 2006 Culture Collection and NIH-3T3 and CCK2R-E151A cells (E151A) were obtained as previously described (Gales et al., 2003) . SW-620 and MCF-7 were, unless otherwise indicated, routinely grown in RPMI 1640 growth medium containing 5% fetal bovine serum (FBS) (Invitrogen, Carlsbad, CA), 2 mM glutamine, and 50 units/ml of both penicillin and 
for 5 days in phenol red-free medium, containg 5% dextran-coated charcoal-treated FBS.
Luciferase assay were carried out exactly as previously described (de Medina et al., 2006) .
Microsomal Antiestrogen Binding Site and ChEH assays:
Competition of binding to the rat liver microsomal AEBS was measured exactly as previously described (Payre et al., 2008) .
Inhibition of ChEH activity was measured as previously described on a whole cell assay using MCF-7 cells (de Medina et al., 2010) . The thermal cycling conditions comprised 2 min at 55°C and 2 min at 95°C followed by 40 cycles at an appropriate annealing temperature depending on the primer set for 1 min. The results were quantified by the comparative C t method using qBASE software.
Progesterone Receptor Expression. For each condition, 9 × 10 5 cells were seeded in 140-mm-diameter dishes and treated, as described above, in a final volume of 15 ml. Cells were incubated for 48 h with E2 or auraptene. Quantification of the progesterone receptor (PR) was carried out on the cytosolic fraction of cells exactly as described in a previous article (de Medina et al., 2006) . In brief, after treatment, the culture medium was removed, and the cells were washed twice with PBS and scraped into 350 μ l of homogenization buffer (10 mM Tris buffer, pH 7.4, containing 20 mM molybdic acid and 12 mM monothioglycerol). The cells For proliferation assays, cells were grown for 5 days in phenol red-free medium containing 5% dextran-coated charcoal-treated FBS. Cells were seeded into 96-well plates at 2000 cells/well. Treatment media (150 μ l/well) were added on the following day and replaced at 48-h intervals until the end of the experiment. Cell density was measured using the tetrazolium reduction assay (Sigma-Aldrich). The absorbance at 540 nm of the formazan was measured directly in the 96-well plates with a multiscan multisoft reader from Thermo Electron Corporation (Waltham, MA).
Clonogenic assay. Cells were trypsinized and plated in 60mm tissue culture plates at a density of 500-1000 per plate. The cells were allowed to adhere for 24 h, and drugs were added to the final concentrations from concentrated stocks. After 24 to 72 h incubation, the plates were washed twice with serum-free medium, fresh medium was added, and the cells were incubated until colonies were visible. The plates were washed once with PBS and stained with Coomassie brilliant blue. Visible colonies were counted and reported as the percentage of control cells (ethanol-treated, 0.01% (v/v) (Fig.3A-B) . In Fig.3B ERβ in a concentration-dependent manner (Fig.3C) , with an IC 50 of 7.8 and 7.9 μM, respectively. By contrast auraptene did not bind to the AEBS (Fig.3C ) and does not inhibit This article has not been copyedited and formatted. The final version may differ from this version. (Fig.3C ) carried out by the AEBS. These data established that auraptene is a ligand of ER with no subtype selectivity and has no affinity for the AEBS.
Effect of auraptene on the cellular distribution of Estrogen Receptor α. We next evaluated the effect of auraptene on the stability of ERα and its distribution in MCF-7 cells.
Cells were fractionated into cytoplasmic, nuclear soluble and nuclear insoluble fractions (Fig.3D ). In the presence of E2, OH-Tam and auraptene, the ERα was translocated from the cytoplasm to the nuclear fractions (approximatively 20% of the total cellular ER). The nuclearization of the ER showed that the interaction between auraptene and the receptor was functional. By contrast, in the presence of ICI, the ER was enriched in the nuclear insoluble fraction compared with solvent vehicle treated cells (Fig.3D ). These data established that, similarly to SERMs, auraptene induces nuclear relocalization of the ERα.
Auraptene is a partial agonist of estrogen receptor-dependant transcription. The ability of auraptene to bind to ERs raised the possibility that it might act as an ER agonist or antagonist and so we decided to evaluate experimentally the agonist/antagonist properties of auraptene. We used MCF-7 cells stably transfected with a plasmid encoding an estrogenresponsive promoter fused to the luciferase gene that were called MELN (de Medina et al., 2006) . Auraptene stimulated the expression of luciferase in MELN cells in a concentrationdependent manner with an EC 50 of 3.6 ± 1.1 μM and reached a plateau at 20 μM (Fig.4A), representing 51% of the maximal response observed with E2 (Fig. 4B ). This agonist activity was observed in a range of concentrations consistent with the binding affinity of auraptene to the ER, and this stimulation was inhibited by co-treatment with the antiestrogen ICI 164,384
( Auraptene modulates the expression of endogenous estrogen receptor-regulated genes.
To determine whether auraptene could modulate the expression of endogenous E2-regulated genes as well as reporter genes, the expression of the progesterone receptor (PR), TFF1 (Ps2) and TGFα were measured by quantitative RT-PCR in MCF-7 cells treated with or without auraptene (20 μM) or E2. Figure 4C shows that auraptene slightly modulated the transcription of TGFα (x 1.1) and inhibited the expression of Ps2 (x 0.5). In addition we showed that auraptene antagonized the stimulation by E2 of Ps2 and TGFα expression with IC 50 of 4.50 ± 0.9 µM and 3.38 ± 0.8 µM respectively (Fig. 4D) . Auraptene stimulated the expression of PR at the mRNA (Fig. 4E ) and at the protein levels (Fig. 4E ). These data established that auraptene is a modulator of the transcription of genes that are known to be under control of ER.
Auraptene controls the proliferation of tumor cells lines and blocks the invasiveness and
colony formation of tumor cells. We next evaluated the effect of auraptene on the proliferation and invasiveness of cell lines. Auraptene induced concentration-dependent growth control (Fig 5A) through an arrest of the cell cycle in the G0-G1 phase in the 4 tumor cell lines (Fig. 5B) showing that auraptene inhibited both the proliferation of ER+ (MCF-7)
and ER-(MDA-MB-231) human breast cancer cells; it inhibited the stimulation of MCF-7
proliferation by E2 as observed with estrogen antagonists (Fig. 5C ). In addition, Fig. 5D shows that auraptene reduced cell survival in a clonogenic assay causing a 50 %, 69 %, 68 % (Fig. 5E ). These data establish that auraptene reduces the proliferation, viability and invasiveness of tumor cells of different origins.
Discussion
In this study, we report the identification of two molecular targets of auraptene that explains its chemopreventive and anticancer properties. Using a pharmacophore approach, we hypothesized that auraptene could be both an inhibitor of cholesterol esterification and a modulator of ERs and this was confirmed experimentally. Auraptene was a potent ACAT inhibitor with liver extracts and intact tumor cells suggesting that cholesterol esterification is part of its mechanism of action and was a direct estrogen receptor modulator. No affinity for the AEBS was observed, consistent with the absence of the required protonatable dialkylaminoethoxy side chain on auraptene (de Medina et al., 2004a) . Consistently with its lack of affinity for the AEBS, auraptene did not inhibit the cholesterol-5,6-epoxide hydrolase activity which is carried out by the AEBS. Since auraptene bound to ERs with µM affinities and modulated the transcription of reporter and endogenous genes under their transcriptional control, we established that it stimulates the expression of the progesterone receptor but acted as an antagonist to the expression of TGF-α or Ps2. Morever, auraptene brought about the relocalization of ERs from the cytoplasm to the nucleus as observed with E2 and SERMs.
Auraptene did not stimulate the growth of ER expressing cells, showing that it showed one of the expected properties of a SERM in that it acts as an antagonist on TGF-α expression and sustains the lack of mitogenicity on estrogen responsive cells. This makes it unlikely that auraptene risks causing endometrium cancer development as observed with certain SERMs such as tamoxifen (Jordan, 2003) . The involvement of ERs in the anti-inflammatory properties of aurapene (Epifano et al., 2008) 
In vitro tests with auraptene are usually conducted at concentrations ranging from 10 to 50 µM (Epifano et al., 2008) . At these concentrations both ER modulatory activity and ACAT inhibition occurred. Auraptene is well tolerated in rodents and does not show any toxicity up to 1000 mg/kg (Tanaka et al., 2000) . When used at 500 ppm (40 mg/kg) as a dietary additive, it has been shown to be present in the mammary glands of treated animals at concentrations ranging from 0.5 to 3.5 µM (Krishnan et al., 2009) . Given that the IC 50 of the regulation of ER-dependent transcription in our study was 3.5 and 4.5 µM, ER modulation will be fully This article has not been copyedited and formatted. The final version may differ from this version. 
